Form D · Biotechnology

Glenveigh Pharmaceuticals, LLC

Chattanooga, TN · CIK 0001535853

Offering snapshot reported May 14, 2012 · SEC filing

Reported sold
$1.1M
Offering amount: $1.75M
Investors reported
1
Form D · investor count
Minimum accepted
$50K
Reported outside-investor minimum
First sale
Apr 30, 2012
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 14, 2012Initial$1,100,000No comparison1SEC filing
Nov 29, 2011Initial$250,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$55K (estimated)
Form D file number
021-178203
Issuer reimbursing investor partnership for its financial representative (Mr. Pippenger) costs by issuing additional membership interest (LLC Units) in Issuer equal to 5% of the amount purchased by investor partnership.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Robert Dean Pippenger, Jr.1767892

Source: Form D, filed May 14, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Charles David Adair Director, Executive
Richard Becherer Director
Ken Couch Director
Mark David Hackett Director
Lizbeth Kennedy Thomas Director
Richard C Proctor, Jr. Director, Executive
William R Russell Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
401 Chestnut Street Suite 230
Chattanooga, TN, 37402